

Updates on Urothelial Carcinoma
Live Virtual Course | Date: September 6, 2024

Premier Sponsor



Friday, September 6, 2024		
Time (Mountain Time)	Topic	Presenter(s)
8:00-8:15 am	Welcome and Introductions	<i>Dr. Christine Mullin, Dr. Zachary Wright</i>
8:15-8:45 am	Lapatinib Therapy in Canine Urothelial Carcinoma: From Molecular Insights to Clinical Outcomes <ul style="list-style-type: none"> • Role of HER2 in canine urothelial carcinoma • Molecular mechanisms of antitumor effects in lapatinib • Efficacy of lapatinib in canine urothelial carcinoma • Adverse events of lapatinib in dogs 	<i>Dr. Shingo Maeda</i>
8:45-9:15 am	Advances in Urothelial Carcinoma <ul style="list-style-type: none"> • Have a broad knowledge of canine invasive urothelial carcinoma. • Know avoidable risk factors for the cancer. • Understand the benefit of early detection and early intervention. 	<i>Dr. Debbie Knapp</i>
9:15-9:45 am	Molecular Signatures of Canine Urothelial Carcinoma <ul style="list-style-type: none"> • Gain knowledge about the types of somatic variants that are evident in tumor samples of canine urothelial carcinoma • Understand the need for rigorous validation of next generation sequencing data • Understand how a broad sweep of the genome can lead to highly focused molecular testing to detect the presence of targeted variants in clinical specimens • Learn how such testing is being used to detect and monitor disease progression in clinical cases • Appreciate the need for continuous scientific rigor and data interpretation at all stages of the process 	<i>Dr. Matthew Breen</i>
9:45-10:00 am	Break	
10:00-11:00 am	KEYNOTE: Novel Therapeutic Approaches in Advanced Bladder Cancer: Potential Opportunities for Veterinary Translation	<i>Dr. Jonathan Rosenberg</i>
11:00 am-12:00 pm	Panel Discussion on Morning Topics	<i>Dr. Jonathan Rosenberg Dr. Debbie Knapp Dr. Matthew Breen Moderator: Zachary Wright</i>

Updates on Urothelial Carcinoma
Live Virtual Course | Date: September 6, 2024

Premier Sponsor



Friday, September 6, 2024		
Time (Mountain Time)	Topic	Presenter(s)
12:00-12:30 pm	Lunch Break	
12:30 – 1:00 pm	Lunch & Learn – Presented by Nutramax	
1:00-1:30 pm	<p>Radiotherapeutic Approaches to Canine Urothelial Carcinoma</p> <ul style="list-style-type: none"> Understand the role of low intensity palliative intent radiotherapy for management of canine urothelial carcinoma; be able to describe commonly used treatment protocols and associated clinical outcomes. Understand the role of radiotherapy in a definitive-intent multimodal treatment approach for canine urothelial carcinoma. Be able to describe how radiotherapy is prescribed in this setting, and how it can be interfaced with other standard therapies such as chemotherapy and surgery. 	<i>Dr. Mike Nolan</i>
1:30-2:00 pm	<p>Novel Lower Urinary Tract Interventional Oncology Options</p> <ul style="list-style-type: none"> Attendees will learn how intra-arterial chemotherapy is performed and what outcomes have been achieved. Current results of prostatic artery embolization will be discussed as will major complications. Ablation will be explained and applications in urinary tract disease will be discussed. 	<i>Dr. William Culp</i>
2:00-2:15 pm	Break	
2:15-2:45 pm	<p>Updates on Surgical Treatment Options for Urothelial Carcinoma</p> <ul style="list-style-type: none"> List the surgical treatment options for urothelial carcinoma of the bladder and prostate. Relate the patient selection criteria for partial cystectomy, total cystectomy, and prostatectomy for urothelial carcinoma. Discuss the complications and expected outcomes for partial cystectomy, total cystectomy, and prostatectomy for urothelial carcinoma. 	<i>Dr. Laura Selmic</i>

Updates on Urothelial Carcinoma
Live Virtual Course | Date: September 6, 2024

Premier Sponsor



Friday, September 6, 2024		
Time (Mountain Time)	Topic	Presenter(s)
2:45-3:15 pm	<p>Cystoscopic Ablation of Urothelial Carcinoma</p> <ul style="list-style-type: none"> • At the end of this lecture, attendees will be able to • Identify suitable candidates for cystoscopic ablation of urothelial carcinoma • Compare cystoscopic ablation with other approaches such as urethral stent placement • Incorporate cystoscopic ablation into management protocols for patients with urothelial carcinoma 	<i>Dr. Audrey Cook</i>
3:15-4:15 pm	Panel Discussion on Afternoon Topics	<p><i>Dr. Mike Nolan, Dr. William Culp, Dr. Laura Selmic, Dr. Audrey Cook</i></p> <p><i>Moderator: Christine Mullin</i></p>
4:15-4:30 pm	Closing Remarks	<i>Dr. Christine Mullin</i>